Down 21% in 3 months while the S&P 500 was flat.
−2Long-term trend
IRWD's Quality Score fell 2 points on Fri, Oct 30, to 9. Buying volume slipped off its 20-day high (2 chart checks stopped).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| The company | Sales up 26% on the year |
| Latest filing | 8-K, Oct 16 |
ReportReports Thursday, before the open. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, +2.4% on average. Past reports ›
Ironwood Pharmaceuticals, Inc. - filed an 8-K reporting a change of CEO
IRWD closed −7.2% that day.
After its last 4 reports it closed +2.4% on average, higher 2 of 4 times.
IRWD is #43 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 43 |
Reports Thu Nov 5, before the open (in 3 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
IRWD's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| LINZESS U.S. net sales | $1.15B to $1.20B |
Sales fell 5.3% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 0.3% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 6, 2026 | +0.2% | +2.6% | +4.1% |
| May 7, 2026 | -3.1% | -13.7% | -23.8% |
| Feb 25, 2026 | -5.0% | -11.3% | -4.0% |
Sales grew in three of the last seven years, to $296M in 2025. It made a profit in six of the eight years.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: IRWD is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
“Linaclotide competes globally with certain branded and generic prescription therapies and over-the-counter, or OTC, products for the treatment of IBS-C and CIC, or their associated symptoms.”
IRWD scores 9 today, which Breakaway calls Average. It is #43 of 291 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 21% in 3 months while the S&P 500 was flat. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
IRWD scores 9 today, which Breakaway calls Average (6 to 10). That is #43 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind IRWD's 9.
Reports Thu Nov 5, before the open, a date the company confirmed. IRWD closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.